Highlights

  • Acrux raised $1.6 million through a share Placement to institutional and professional investor.
  • Placement attracted binding commitments totalling $2.6 million and was scaled back by $1 million.
  • Funds will support development of Acrux’s female testosterone program
  • Capital will also assist the company as it progresses co-development discussions with an international partner.
  • Placement shares were issued at 0.95 cents per share.
  • Investors may receive one attaching option for every two shares subscribed, subject to Shareholder approval

Acrux Limited (ASX:ACR) shares moved higher during the afternoon session on 11 May 2026 after the specialty pharmaceutical company announced it had secured binding commitments to raise $1.6 million through a share placement.

The stock traded at AUD 0.012, up 9.09% for the session, with investors responding positively to the funding update and the level of Demand received from institutional and professional investors.

Despite the intraday rise, Acrux shares remain approximately 60% lower over the past year as the company continues progressing development activities across its pharmaceutical pipeline.

According to Acrux, the placement received commitment bids totalling approximately $2.6 million, resulting in the offer being scaled back by around $1 million.

Management said the capital raising attracted support from both new and existing investors.

Company Overview

Acrux Limited is an Australian specialty pharmaceutical company focused on the development and commercialisation of topically applied pharmaceutical products.

The company has more than 25 years of experience developing pharmaceutical technologies and has commercialised several products globally through licensing arrangements.

Acrux has historically maintained a particular commercial focus on the United States market through partnerships and licensee agreements.

Its current pipeline strategy includes advancing female testosterone development alongside broader pharmaceutical opportunities within topical and transdermal therapies.

Funding To Support Female Testosterone Development

Acrux stated that proceeds from the placement will primarily be directed toward the ongoing development of its female testosterone program.

The company also plans to use part of the funding to support activities associated with reaching a co-development agreement with an international partner.

Management indicated that the female testosterone opportunity remains a central strategic focus for the company as it advances development work targeting women affected by hypoactive sexual desire dysfunction (HSDD).

Acrux Chief Executive Officer and Managing Director John Warmbrunn said the level of investor participation reflected favourable interest in the company’s clinical development pathway.

According to Warmbrunn, excess demand for the placement demonstrated investor attention toward the company’s Phase III clinical trial activities and potential co-development opportunities.

Management also highlighted Acrux’s existing commercialised portfolio and long-standing experience in topical pharmaceutical development as supportive factors for future growth initiatives.

Placement Structure and Pricing Details

The placement was conducted at an issue price of 0.95 cents per new share.

Acrux noted that the Offer Price represented a discount of 13.6% to the company’s last traded share price of 1.10 cents and a discount of 16.8% to the five-day Volume weighted average price (VWAP) of 1.14 cents per share up to 9 May 2026.

The company confirmed the placement was made to institutional and professional investors.

In addition to the placement shares, Acrux also intends to offer participants one free attaching option for every two shares subscribed for under the raising, subject to shareholder approval.

The proposed attaching Options will carry an exercise price of 1.8 cents and will expire three years after issuance.

The option component is expected to be presented to shareholders for approval at an Extraordinary General Meeting anticipated to take place in July 2026.

Acrux said further details relating to the attaching options will be included in the notice of meeting documentation ahead of the shareholder vote.

Lead Manager Fees and Capital Structure

The company also outlined fee arrangements associated with the placement.

Acrux confirmed that Alpine Capital acted as Lead Manager for the raising.

As part of the arrangement, Alpine Capital will receive six options for every share issued under the placement, excluding shares issued to participants introduced directly by Acrux.

These options are expected to be issued on the same terms and at the same time as the attaching options proposed for placement participants.

The company did not indicate any changes to broader operational guidance in the announcement, with the focus remaining on funding development activities and advancing strategic Partnership discussions.

Focus Remains on Pharmaceutical Pipeline Progress

The latest capital raising comes as Acrux continues progressing its pharmaceutical development strategy built around topically applied products.

The company has increasingly focused attention on the female testosterone opportunity, which management believes addresses an area of unmet medical demand.

Acrux stated that the additional funding is intended to support ongoing clinical development activity as it works toward securing a co-development pathway with an international partner.

Management also emphasised the company’s experience in developing and commercialising topical pharmaceutical products over more than two decades.

The company believes its historical expertise in transdermal and topical drug delivery may support future commercial opportunities within its pipeline.

Investor Takeaway

Acrux’s latest update appeared to improve investor sentiment during Monday’s session, with shares moving higher following the announcement of a heavily subscribed placement.

The funding provides additional capital to support the company’s female testosterone development program and co-development discussions with an international partner, both of which remain central to Acrux’s broader strategic direction.

Investors are likely to continue monitoring progress surrounding the company’s Phase III activities, partnership pathway and future funding requirements, particularly given the heightened interest reflected in the oversubscribed placement.

The proposed attaching options and future shareholder approval process may also remain in focus over coming months as the company advances its clinical and commercialisation objectives.